Literature DB >> 22359106

Managing risks of neoplasia in inflammatory bowel disease.

Fernando Velayos1.   

Abstract

Inflammatory bowel disease (IBD) has been linked with a variety of intestinal and extraintestinal cancers. This review summarizes the latest literature with regard to which cancers are truly linked with IBD and which are not, the absolute and relative risks of these cancers, how medications commonly prescribed for IBD affect this risk, and finally strategies for managing these risks. Physicians and health professionals may find this information useful for counseling and educating patients as well as for improving patient care.

Entities:  

Mesh：

Year:  2012        PMID： 22359106     DOI： 10.1007/s11894-012-0247-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  50 in total

1.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

Review 2.  AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease.

Authors:  Francis A Farraye; Robert D Odze; Jayne Eaden; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2010-02       Impact factor: 22.682

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Inflammatory bowel disease is not associated with an increased risk of lymphoma.

Authors:  J D Lewis; W B Bilker; C Brensinger; J J Deren; D J Vaughn; B L Strom
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682

6.  Lack of association between cervical dysplasia and IBD: a large case-control study.

Authors:  C W Lees; J Critchley; N Chee; T Beez; R E Gailer; A R Williams; A G Shand; I D R Arnott; J Satsangi
Journal:  Inflamm Bowel Dis       Date:  2009-11       Impact factor: 5.325

7.  Small intestinal adenocarcinoma in Crohn's disease: a case-control study.

Authors:  Craig A Solem; W Scott Harmsen; Alan R Zinsmeister; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2004-01       Impact factor: 5.325

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.

Authors:  James F Marion; Jerome D Waye; Daniel H Present; Yuriy Israel; Carol Bodian; Noam Harpaz; Mark Chapman; Steven Itzkowitz; Adam F Steinlauf; Maria T Abreu; Thomas A Ullman; James Aisenberg; Lloyd Mayer
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

10.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321
View more
  3 in total

1.  Risk of cancer, with special reference to extra-intestinal malignancies, in patients with inflammatory bowel disease.

Authors:  Alicia Algaba; Iván Guerra; Angel Castaño; Gema de la Poza; Víctor M Castellano; Montserrat López; Fernando Bermejo
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review.

Authors:  Ammar Hassanzadeh Keshteli; Vickie E Baracos; Karen L Madsen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

3.  Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis.

Authors:  Jessica R Allegretti; Edward L Barnes; Anna Cameron
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.